CD8A and B-cell chronic lymphocytic leukemia: After 4 weeks of ibrutinib treatment, T cell numbers and the percentage of CD4 T cells, memory CD8 (CD45RO+) T cells and Tregs as well as IL-10 concentration are reduced in CLL patients (Podhorecka et al., 2017).